Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …

Introduction Hypomethylating agents (HMAs) seem to have a range of properties favorable
to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute …

The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-
related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction of …

Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age
70 to 72 years and represents one of the most effective curative treatments for many …

As in younger patients, allogeneic stem cell transplantation (alloHSCT) offers the best
chance for durable remission in older patients (≥ 60 years) with acute myeloid leukemia …

Despite advances in the clinical management of childhood acute myeloid leukemia (AML)
during the last decades, outcome remains fatal in approximately one third of patients …

Purpose This study assessed and compared preferences for treatment attributes of
maintenance therapies post-hematopoietic stem cell transplantation (HSCT) in patients with …

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid
leukemia (AML) in first complete remission is a central treatment paradigm to achieve …

Abstract This 3+ 3 dose-escalation phase I multicenter study investigated the optimal dose of
azacitidine (AZA) for post-hematopoietic stem cell transplantation (HSCT) maintenance …

Relapse remains the most critical obstacle in treatment by allogeneic hematopoietic stem
cell transplantation (HSCT). Non-relapse mortality has improved annually, but relapse …